Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $17.98
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 13, 26 |
Daily · Wilder smoothing
| BTIG |
| maintain |
| Buy |
| Buy |
| Oct 1, 26 | Guggenheim | maintain | Buy | Buy |
| Sep 18, 26 | BTIG | maintain | Buy | Buy |
| Aug 7, 26 | Guggenheim | maintain | Buy | Buy |
| Aug 7, 26 | Needham | maintain | Buy | Buy |
| Jul 24, 26 | BTIG | maintain | Buy | Buy |
| Jun 3, 26 | Craig-Hallum | maintain | Buy | Buy |
| May 20, 26 | Keybanc | maintain | Overweight | Overweight |
| May 5, 26 | Needham | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 58.46 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 77.01 | Oscillator | Neutral |
| Williams %R (14) | -28.85 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.28 (Hist 0.05) | Oscillator | Strong Buy |
| Average Directional Index (14) | 16.89 (+DI 23.2 / -DI 16.4) | Trend | Neutral |
| EMA 20 | 17.33 | MA | Strong Buy |
| SMA 20 | 17.38 | MA | Strong Buy |
| EMA 50 | 16.76 | MA | Strong Buy |
| SMA 50 | 16.72 | MA | Strong Buy |
| SMA 200 | 13.12 | MA | Strong Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 11, 26 | Shelton Jerrell | director, officer: President, CEO | S-Sale | 28,800 @ $14.91 | $429.4K |
| Jun 11, 26 |
| Zecchini Edward J |
| officer: Chief Digital and Tech Officer |
| M-Exempt |
| 33,600 @ $4.80 |
| $161.3K |
| Jun 10, 26 | Zecchini Edward J | officer: Chief Digital and Tech Officer | M-Exempt | 1,400 @ $4.80 | $6.72K |
| Jun 11, 26 | Zecchini Edward J | officer: Chief Digital and Tech Officer | S-Sale | 33,600 @ $14.47 | $486.2K |
| Jun 10, 26 | Zecchini Edward J | officer: Chief Digital and Tech Officer | S-Sale | 1,400 @ $15.23 | $21.32K |
| Jun 10, 26 | Zecchini Edward J | officer: Chief Digital and Tech Officer | M-Exempt | 1,400 @ $4.80 | $6.72K |
| Jun 11, 26 | Zecchini Edward J | officer: Chief Digital and Tech Officer | M-Exempt | 33,600 @ $4.80 | $161.3K |
| Jun 5, 26 | Baddour Linda | director | A-Award | 10,350 | — |
TTM vs. 5-year historical average (annual ratios)
| Metric | CYRX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -21.9x | -5.1x · sector 18.4x | Discount |
| Forward P/E (FY26E) | -22.8x | EPS est. -0.79 | In line |
| Price / Book | 1.8x | 1.8x | In line |
| Price / Sales | 4.9x | 4.7x | In line |
| EV / EBITDA | -279.1x | -203.3x | Elevated |
| Return on equity | -7.2% | — | Weak |
| Gross margin | 47.1% | 44.1% | In line |
| Debt / Equity | 0.47 | 0.68 | Conservative |
| Piotroski / Altman Z | 3/9 | Z 1.25 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G/A | Aug 14, 2026 | 2026-08-14 15:34:35 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 17:05:39 | View |
| 4 | Aug 11, 2026 | 2026-08-11 18:49:32 | View |
| 10-Q | Aug 6, 2026 | 2026-08-06 17:03:03 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:30:48 | View |
| SC 13G/A | Jul 29, 2026 | 2026-07-29 17:50:37 | View |
| S-8 | Jun 22, 2026 | 2026-06-23 07:51:16 | View |
| 15-12G | Jun 22, 2026 | 2026-06-22 17:21:53 | View |
| 4 | Jun 12, 2026 | 2026-06-12 18:38:03 | View |
| 8-K | Jun 9, 2026 | 2026-06-09 17:00:27 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2026 on Thursday, November 5, 2026 after U.S. markets close.
Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Cryoport, Inc., rated BUY, is up 82% YTD, driven by robust cell and gene therapy (CGT) commercialization and pipeline momentum. CYRX returned to adjusted EBITDA profitability in 2Q26, with strong Life Science Services growth and positive operating cash flow of $8 million TTM. Management expects 5 new CGT commercial approvals in 2026, supported by a 15% YoY increase in the Phase 3 trial pipeline to 94 trials.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.19 | -0.20 | Miss -3.5% | $48.97M |
| May 4, 2026 | -0.20 | -0.23 | Miss -15.0% | $47.80M |
| Mar 3, 2026 | -0.19 | -0.21 | Miss -10.5% | $45.45M |
| Nov 4, 2025 | -0.23 | -0.18 | Beat 21.7% | $44.23M |
| Aug 5, 2025 | -0.20 | -0.29 | Miss -45.0% | $45.45M |
| May 7, 2025 | -0.23 | -0.22 | Beat 4.3% | $41.04M |